Related Experiment Video

Updated: Jun 19, 2026

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

Antiplatelet agents in stroke prevention: acute and long-term treatment strategies

R Weber1, C Weimar, H-C Diener

  • 1Department of Neurology and Stroke Center, University Duisburg-Essen, Essen, Germany.

Hamostaseologie
|November 3, 2009
PubMed

Insights

Aspirin use varies by sex for primary prevention of stroke and myocardial infarction. For secondary prevention and atrial fibrillation, aspirin and anticoagulants offer benefits but carry bleeding risks, requiring individualized treatment choices.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Pharmacology

Background:

  • Antiplatelet and anticoagulant therapies are crucial in cardiovascular and cerebrovascular disease management.
  • Understanding the differential effects of these agents in primary and secondary prevention is essential for clinical practice.
  • Sex-based differences in the efficacy of aspirin for primary prevention warrant further investigation.

Purpose of the Study:

  • To review the efficacy and safety of aspirin and other antithrombotic agents in stroke prevention.
  • To compare aspirin monotherapy with combination therapies and oral anticoagulants in various clinical scenarios.
  • To provide guidance on treatment selection based on patient characteristics and risk profiles.

Main Methods:

  • Review of large randomized trials and clinical guidelines.
  • Analysis of data on aspirin's efficacy in primary prevention stratified by sex.
  • Comparison of aspirin, aspirin/dipyridamole, clopidogrel, and oral anticoagulants in secondary prevention and specific stroke subtypes.

Main Results:

  • In primary prevention, aspirin reduces stroke risk in women and myocardial infarction risk in men.
  • Aspirin is effective within 48 hours of ischemic stroke. Combination therapies (aspirin/dipyridamole, clopidogrel) improve outcomes in secondary prevention but increase bleeding risk.
  • Oral anticoagulants are more effective than aspirin for stroke prevention in atrial fibrillation but carry higher bleeding risks in symptomatic intracranial stenosis. Aspirin is recommended for stroke patients with patent foramen ovale.

Conclusions:

  • Treatment decisions for stroke prevention require careful consideration of agent type, patient sex, stroke subtype, and individual risk factors.
  • While potent antiplatelet agents and anticoagulants offer benefits, their use must be balanced against the risk of bleeding complications.
  • Personalized medicine approaches are key to optimizing antithrombotic therapy for cardiovascular and cerebrovascular protection.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...